Postinflammatory hyperpigmentation - Hiperpigmentasi Postinflamasi
Hiperpigmentasi Postinflamasi (Postinflammatory hyperpigmentation) minangka kondisi kulit sing ditondoi dening tambah pigmen ing kulit sawise inflamasi kulit. hiperpigmentasi postinflamasi (postinflammatory hyperpigmentation) bisa disebabake dening cahya srengenge sing suwe, inflamasi, utawa ciloko kulit liyane, kalebu sing ana hubungane karo kukul. Wong kanthi warna kulit sing luwih peteng biasane luwih rawan hiperpigmentasi kanthi cahya srengenge sing berlebihan.
☆ Ing asil Stiftung Warentest 2022 saka Jerman, kepuasan konsumen karo ModelDerm mung luwih murah tinimbang konsultasi telemedicine sing dibayar.
References
Postinflammatory hyperpigmentation (PIH) minangka masalah kulit sing kerep kedadeyan sawise inflamasi utawa ciloko kulit. Cenderung tahan suwe lan luwih elek ing wong kanthi warna kulit sing luwih peteng (Fitzpatrick skin types III–VI) . Senajan kerep dadi luwih apik dhewe, iki bisa njupuk sawetara wektu, mula perawatan asring dibutuhake kanggo dangu. Nggabungake perawatan sing beda paling apik.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
